Morag Griffin - Concepedia

Author

Morag Griffin

Also Known As

Ataulfo Gonzalez-Fernandez, Luana Marano, M E Griffin, M Griffin, M. E. Griffin, M. Griffin, Morag Griffin, The complement C5 inhibitors eculizumab and ravulizumab are the current standards of care in patients with paroxysmal nocturnal haemoglobinuria (PNH)

137

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

St James's University Hospital Leeds Teaching Hospitals NHS Trust Hôpital Saint-Louis RWTH Aachen University Assistance Publique – Hôpitaux de Paris

About

Morag Griffin is an author at St James's University Hospital specializing in medicine, nephrology, and chronic kidney disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	210
2	Nephrology	3	3	173
3	Endocrinology	1	1	14
4	Immunology	1	1	23
5	Medical Laboratory Science	1	1	30

Morag Griffin

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Peter Hillmen, Jeff Szer, Ilene C. Weitz, New England Journal of Medicine	2021	356
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia Régis Peffault de Latour, Austin Kulasekararaj, Simona Iacobelli, New England Journal of Medicine	2022	265
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria Régis Peffault de Latour, Alexander Röth, Austin Kulasekararaj, New England Journal of Medicine	2024	119
Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline Austin Kulasekararaj, Jamie Cavenagh, Inderjeet Dokal, British Journal of Haematology	2024	85
Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial Jong Wook Lee, Morag Griffin, Jin Seok Kim, The Lancet Haematology ThrombosisHemodialysisSignificant Extravascular HaemolysisMedicineHematology	2023	78
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial Régis Peffault de Latour, Jeff Szer, Ilene C. Weitz, The Lancet Haematology Chronic Kidney DiseaseHematologyPegcetacoplan Versus EculizumabMedicineParoxysmal Nocturnal Haemoglobinuria	2022	65
The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK’s population‐based haematological malignancy research network 2004‐2018 Stephen J. Richards, Daniel Painter, Anita J. Dickinson, European Journal Of Haematology	2021	57
Long‐term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‐year results from two pivotal phase 3 studies Austin Kulasekararaj, Morag Griffin, Saskia Langemeijer, European Journal Of Haematology	2022	56
Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria Richard Kelly, Matthew T. Holt, Jennifer Vidler, Blood	2023	39
Real‐world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria Morag Griffin, Richard Kelly, Isabelle Brindel, American Journal of Hematology	2024	33

Page 1